Navigation For Mobile
  2. >
  3. Blog
  4. >
  5. deuterium exchange

Category Archives: deuterium exchange

Deuterated Drug Molecules: Perfecting the Gamechanger

Posted on December 1, 2021 by

Scientific breakthroughs in the pharmaceutical industry can happen overnight, but it still takes time to perfect a discovery’s applications. Deuterium-labeled active pharmaceutical ingredients (APIs) are one specific advancement that has…

Posted in APIs, deuterated molecule, deuteration, deuterium exchange, drugs | Tagged , , | Comments Off on Deuterated Drug Molecules: Perfecting the Gamechanger

Deuterated Drugs Reach Two-Year Anniversary

Posted on May 15, 2019 by

We’ve reached the two year anniversary of the first FDA approval of a deuterated molecule (April 2017, Teva’s Astedo – a deuterated version of tetrabenazine for the treatment of Huntington’s…

Posted in APIs, Chemistry, CMC, Contract Manufacturing, deuterated molecule, deuteration, deuterium exchange, method development, Neuland Labs, process chemistry | Tagged , , , | Comments Off on Deuterated Drugs Reach Two-Year Anniversary

API Manufacture of Deuterated Molecules

Posted on December 4, 2016 by

Deuterated compounds – in which a drug molecule’s carbon-hydrogen bond is replaced with a carbon deuterium bond to extend the drug’s half-life – continue to show promise in potentially boosting the…

Posted in API synthesis, APIs, CMC, Contract Manufacturing, CRO/CMO, deuterated molecule, deuteration, deuterium exchange, method development | Comments Off on API Manufacture of Deuterated Molecules

What are the Key Differences with Orphan Drug Manufacturing?

Posted on July 3, 2016 by

I was asked recently what a contract manufacturer such as Neuland Labs saw as the key differences with orphan drug projects. Neuland approaches orphan drug projects slightly differently from our…

Posted in deuterium exchange, drugs, FDA, Orphan drug | Comments Off on What are the Key Differences with Orphan Drug Manufacturing?